#ASGCT
NEW RELEASE! An ASGCT Community Quick Take explores key topics from last week's ASGCT Breakthrough event. Learn how researchers are tackling the blood-brain barrier to deliver therapies to more areas of the CNS in this 27-minute video.

https://bit.ly/4iWji6P
November 18, 2026 at 5:18 PM
We had a great time in Nashville last week for our Breakthroughs in Cell + Gene Therapy event! Thank you to everyone who joined us in person or virtually. If you missed us, you can catch up on the latest CGT science with on-demand access, now available! https://learning.asgct.org/courses/355885
November 17, 2026 at 4:55 PM
The conversation in CGT is evolving beyond approvals and trial outcomes. Join the ASGCT Virtual Summit on Long-Term Follow-Up and Patient Outcomes, Dec. 2-3, to explore safety, implementation, patient follow-up, and evidence generation. Agenda + registration: https://bit.ly/4e785ig
November 11, 2026 at 9:24 PM
This isn't just one drug. Two other gene therapy programs reported similar AAV integration-linked tumors in the New England Journal of Medicine this year. Researchers at the ASGCT meeting said it underscores the need to monitor treated tissues.
November 11, 2026 at 12:03 PM
Join us Dec. 9 for a free Regulatory Webinar. Experts will cover PDUFA negotiations, public input, congressional reauthorization, and considerations for CGT stakeholders. Learn more and register: https://bit.ly/4zPqQQk
November 12, 2026 at 10:09 PM
Dr. Paloma Giangrande has committed to a second term as Editor-in-Chief of Molecular Therapy Nucleic Acids (MTNA)!
Listen to the latest episode of the Molecular Therapy podcast to learn more about Paloma and her plans for MTNA in the next 5 years:
The Future of Molecular Therapy Nucleic Acids - ASGCT Podcast Network
We are excited to announce that Dr. Paloma Giangrande has committed to a second term as Editor-in-Chief of Molecular Therapy Nucleic Acids (MTNA). In this episode, Dr. Marcin Kortylewski, the Oligonucleotides: Therapies and Applications section editor of MTNA, interviews Paloma about her journey into science and RNA biology, her perspectives on therapeutic development, her initiatives during her first term as Editor-in-Chief, and her vision for MTNA in the next five years. 
dlvr.it
November 5, 2026 at 3:32 PM
This @financialtimes.com article highlights growing investment in human #EmbryoEditing.

ISCT, alongside ASGCT and ARM, has called for a 10-year moratorium on heritable human genome editing to ensure responsible oversight.

📰 Article: buff.ly/wmjf1Nb
📄 Moratorium: buff.ly/9zAXUr4
October 29, 2026 at 4:03 PM
ASGCT is pleased to be at the #NORDSummit this week! Stop by our booth to connect with our patient education resources (including our new coloring book!) and discuss the latest policies affecting rare disease research and individuals.
October 26, 2026 at 11:49 PM
Congratulations to the 9 ASGCT members elected to the National Academy of Medicine! @nam.edu

Their pioneering research and clinical leadership continue to drive progress in cell and gene therapy and improve patient outcomes worldwide. We're proud to celebrate this outstanding achievement.

#ASGCT
October 22, 2026 at 8:17 PM
Hot off the press! 📢 Our Q3 2026 Gene, Cell and RNA Therapy Landscape Report, developed with Citeline, is here.

Explore seven new approvals, an expanding clinical pipeline and the latest advancements shaping the field.

Read more: https://bit.ly/4ufliLp

#ASGCT #CGT
October 21, 2026 at 5:55 PM
We're back with another SCGE Spotlight! This month, we've got:
- 2 recent publications
- Links to our "Meet the Expert" webinar series recordings
- Upcoming SCGE researcher presentations at ASGCT Breakthroughs

www.linkedin.com/pulse/scge-s...
SCGE Spotlight #7
In this edition of the SCGE Spotlight, we’ve got two recent publications, our “Meet the Expert” webinar series, and upcoming presentations by consortium researchers. Let’s get started.
www.linkedin.com
October 21, 2026 at 1:21 PM
One month to go! Join ASGCT and CHOP on Nov. 20 for a full day focused on the safety, translation, and real-world implementation of AAV & LNP gene therapies.

Gain practical insights from clinical and translational experts and earn CME credit.

🔗 https://bit.ly/4uK4PPz
October 20, 2026 at 6:25 PM
The recording of the latest Molecular Presents webinar, AI-Powered Precision Medicine: From Biomarker Discovery to Therapeutic Design and Delivery, is now available!

Watch it here today: http://dlvr.it/TVmhly

#AI #MachineLearning #RNA #ASGCT
Molecular Therapy Presents: AI-Powered Precision Medicine:… | ASGCT
Artificial intelligence is rapidly transforming every stage of precision medicine, from discovering disease biomarkers to engineering targeted delivery…
dlvr.it
October 4, 2026 at 3:55 PM
Be part of what's next in 2027. ASGCT members are invited to renew their membership for the coming year.

Not a member? It's the perfect time to join. https://bit.ly/4yvcuUq
October 2, 2026 at 8:05 PM
Registration is now open for the next Molecular Therapy Presents webinar, Beyond prevalence: How rare diseases are shaping therapeutic innovation. Learn more and register here today: http://dlvr.it/TVlH1Z

#RareDisease #GeneTherapy #CellTherapy #ASGCT
October 2, 2026 at 12:15 PM
The latest episode of the Molecular Therapy Podcast is live! Tune in as Robert Carlisle and Brannon Nicholls discuss their article, Normothermic perfusion of human livers for studying lentiviral vector pharmacokinetics and transduction.

Listen here: http://dlvr.it/TVlHDs

#LentiviralVector #ExVivo
An Ex Vivo Human Liver Model for Lentiviral Vector Profiling | ASGCT
This episode, hosted by Daniel Stone, Associate Editor-in-Chief of Molecular Therapy Advances, focuses on the article, Normothermic perfusion of human…
dlvr.it
October 2, 2026 at 12:21 PM
ASGCT and NTSAD are launching the inaugural NTSAD-ASGCT Translational Research Fellowship Program to help advance innovative genetic medicine research for rare neurogenetic diseases.

Learn more about the fellowship, eligibility criteria and application deadlines: https://bit.ly/4hciETk
September 24, 2026 at 5:00 PM
Join the 2026 NORD Breakthrough Summit, Oct. 25–27 in Washington, D.C.! ASGCT staff will be there to connect you with patient education resources and discuss the latest policies affecting rare disease research and individuals. Learn more ➡️ nordsummit.org

#NORDSummit #RareDisease
September 23, 2026 at 4:27 PM
TODAY at 11 AM CDT: Molecular Therapy Presents - AI-Powered Precision Medicine: From Biomarker Discovery to Therapeutic Design and Delivery

Join us for this exciting FREE webinar today: http://dlvr.it/TVcMM4

#ArtificialIntelligence #GeneTherapy #RNAtherapeutics #ASGCT
Molecular Therapy Presents: AI-Powered Precision Medicine: From…
Join industry experts for a free deep dive into how artificial intelligence is transforming precision medicine. Learn how AI tools are optimizing drug…
dlvr.it
September 23, 2026 at 2:03 PM
Join @spgatucsf.bsky.social and @scopepolicy.bsky.social for this FREE hybrid Science Policy Resume Workshop led by @abankston.bsky.social, a research advocate, government relations advisor, and former AAAS/ASGCT Congressional Policy Fellow. Tue 9/29 12pm PT/3pm ET. tinyurl.com/scipol-res
September 20, 2026 at 3:00 PM
Join us on Sept. 23 at 11 AM CDT for our next exciting free webinar, Molecular Therapy Presents: AI-Powered Precision Medicine: From Biomarker Discovery to Therapeutic Design and Delivery.

Learn more and register here today: http://dlvr.it/TVD1kk

#AI #MachineLearning #ASGCT
Molecular Therapy Presents: AI-Powered Precision Medicine: From…
Join industry experts for a free deep dive into how artificial intelligence is transforming precision medicine. Learn how AI tools are optimizing drug…
dlvr.it
August 28, 2026 at 4:41 PM
Registration is now open for Molecular Therapy Presents - Beyond prevalence: How rare diseases are shaping therapeutic innovation

Save the date, October 21 at 11 AM CDT, and register today: http://dlvr.it/TV8VrM

#RareDisease #ASGCT
Molecular Therapy Presents: Beyond prevalence: How rare diseases are shaping therapeutic innovation
dlvr.it
August 24, 2026 at 2:34 PM
"Statistically significant differences were observed on all key endpoints; Significant functional benefits for 8 and 9-year-olds with Duchenne in Part 2 of the EMBARK study" #Elevidys delandistrogene moxeparvovec #Duchenne muscular dystrophy #GeneTherapy investorrelations.sarepta.com/news-release...
May 16, 2025 at 4:31 PM